Piper Jaffray Downgrades Anthera Pharma (ANTH) to Underweight; PT $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
March 12, 2018 8:00 AM EDTSollpura did not achieve the primary endpoint of the coefficient of fat absorption (CFA)Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (CNA)Further development of Sollpura to be discontinuedAnthera to evaluate all strategic alternativesAnthera to host teleconference today at 8:30 am ET
HAYWARD, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:... More
